P
UTMD icon

&Partners’s Utah Medical Products UTMD Stock Holding History

&Partners’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
5,125
+122
+2% +$8.11K ﹤0.01% 2038
2026
Q1 		$310K Buy
5,003
+1,207
+32% +$76K ﹤0.01% 1972
2025
Q4 		$212K Buy
3,796
+396
+12% +$23K ﹤0.01% 2112
2025
Q3 		$214K Buy
+3,400
New +$201K ﹤0.01% 1934

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

&Partners's UTMD Position: Q2 2026 in Review

&Partners increased its Utah Medical Products (UTMD) stake by 2.4% in Q2 2026, buying an estimated $8.11K and bringing the position to 5,125 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

&Partners first reported a position in UTMD in Q3 2025 and has held it in 4 quarters since. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • &Partners held 5,125 shares of Utah Medical Products worth $354K as of Q2 2026.
  • &Partners bought 122 Utah Medical Products shares in Q2 2026, an estimated $8.11K.
  • Utah Medical Products made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2038 holding.
  • &Partners first reported a position in Utah Medical Products in Q3 2025 and has held it in 4 quarters since.
  • 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.